
News and Publications
Publication Categories
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
7 Hills Pharma, in collaboration with MD Anderson and Texas Heart Institute, published a groundbreaking study in The Journal of Clinical Investigation showcasing how 7HP349 can convert "cold" melanoma tumors into "hot," T cell-enriched tumors, enhancing the efficacy of immune checkpoint blockade therapies. This novel approach offers a promising step forward in cancer immunotherapy.
7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies
7 Hills Pharma secures broad USPTO patent protection for its integrin activators, positioning the company as a key partner for immuno-oncology and COVID-19 vaccine developers. FDA-approved IND trials set to begin soon.